Hostname: page-component-77c89778f8-vsgnj Total loading time: 0 Render date: 2024-07-19T05:28:25.340Z Has data issue: false hasContentIssue false

Fahr’s Disease Presenting as Late-Onset Levodopa-Responsive Parkinsonism

Published online by Cambridge University Press:  16 January 2017

Niraj Kumar
Affiliation:
Department of Clinical Neurological Sciences, Western University, London, ON, Canada.
Mandar Jog*
Affiliation:
Department of Clinical Neurological Sciences, Western University, London, ON, Canada.
*
Correspondence to: Mandar Jog, 339 Windermere Road, A10-026, Department of Clinical Neurological Sciences, London Health Sciences Centre, Western University, Lawson Health Research Institute, London, ON, Canada, N6A 5A5. Email: mandar.jog@lhsc.on.ca
Rights & Permissions [Opens in a new window]

Abstract

Type
Neuroimaging Highlights
Copyright
Copyright © The Canadian Journal of Neurological Sciences Inc. 2017 

A 75-year-old man with no significant past medical illness or pertinent family history presented with insidious onset, gradually progressive, asymmetrical parkinsonism of 1 year’s duration. He had no history of mood disorders, psychosis, or cognitive decline. On neurological examination, his Unified Parkinson’s Disease Rating Scale motor score was 25/108 with asymmetrical rest tremor, rigidity, and bradykinesia, predominantly involving right-sided extremities. He had a slow shuffling gait and reduced right arm swing. The remainder of his neurological examination was normal. He was started on levodopa-carbidopa (100/25 mg) 1 tablet by mouth four times per day. On follow-up 6 months later, his Unified Parkinson’s Disease Rating Scale motor score reduced by 64% to 9/108 with a global improvement in parkinsonism. After a fall, noncontrast computed tomography (CT) scan of the brain revealed calcification involving bilateral basal ganglia, thalamus, subcortical white matter, and cerebellum (Figure 1). Laboratory workup showed normal serum parathyroid hormone, calcium, and phosphate. Genetic testing revealed a heterozygous mutation c.1507G>A (p.Gly503Ser) in exon 8 of the SLC20A2 gene, suggestive of idiopathic basal ganglia calcification (IBGC), also known as Fahr’s disease or primary familial brain calcification, a form of bilateral striopallidodentate calcinosis (BSPDC).Reference Nicolas, Charbonnier and de Lemos 1 , Reference Savino, Soavi and Capatti 2 BSPDC can be autosomal dominant, sporadic, familial (occurrence in multiple family members by chance), or secondary.Reference Savino, Soavi and Capatti 2 The first three subtypes belong to Fahr’s disease or IBGC, a rare neurodegenerative disorder.Reference Savino, Soavi and Capatti 2 Secondary BSPDC, known as Fahr’s syndrome, is linked to calcium and phosphate metabolism defects, infectious or neoplastic brain disorders, previous head trauma, and systemic lupus erythematosusReference Savino, Soavi and Capatti 2 ; therefore, laboratory workup is essential when assessing a possible IBGC patient. Our patient had the sporadic subtype.

Figure 1 Noncontrast CT of the brain showing bilateral calcifications in the basal ganglia and thalamus (A), subcortical white matter (B), and cerebellum (C).

IBGC usually manifests in third through sixth decades,Reference Nicolas, Charbonnier and de Lemos 1 , Reference Manyam, Walters and Narla 3 with a median age of onset at 31 years.Reference Nicolas, Charbonnier and de Lemos 1 Men are affected more commonly than females.Reference Nicolas, Charbonnier and de Lemos 1 , Reference Manyam, Walters and Narla 3 Mutations in three genes including SLC20A2, PDGFRB, and PDGFB, are identified in 50% of cases, indicating the possibility of involvement of other genes yet to be reported.Reference Lemos, Ramos and Legati 4 SLC20A2 mutations account for nearly half of the identified cases.Reference Nicolas, Charbonnier and de Lemos 1 IBGC usually presents with psychiatric features (75.8%), movement disorders (60.6%), and cognitive impairment (57.8%).Reference Nicolas, Charbonnier and de Lemos 1 Movement disorders are more frequent in patients with SLC20A2 mutations, with parkinsonism being the most common (92%).Reference Nicolas, Charbonnier and de Lemos 1 Although psychiatric features and cognitive decline are common in early-onset cases (before 18 years of age), movement disorders predominate in late-onset cases (after 53 years of age).Reference Nicolas, Charbonnier and de Lemos 1 Other neurological manifestations including speech disorder, gait abnormality, cerebellar ataxia, pyramidal features, and seizures may be seen in patients with IBGC.Reference Nicolas, Charbonnier and de Lemos 1 , Reference Manyam, Walters and Narla 3 Up to one-third of patients may remain asymptomatic.Reference Nicolas, Charbonnier and de Lemos 1 , Reference Manyam, Walters and Narla 3

The clinical status correlate with the total calcification score (a visual rating scale of calcification on CT of the brain), with symptomatic patients having a higher score.Reference Nicolas, Charbonnier and de Lemos 1 , Reference Manyam, Walters and Narla 3 The total calcification score increases with age and is higher in males and those having mutations involving SLC20A2 gene.Reference Nicolas, Charbonnier and de Lemos 1 Symptomatic drug therapy for various neuropsychiatric features may be helpful, and levodopa-responsiveness has been reported in up to two-thirds of patients of IBGC with parkinsonism in two separate studies.Reference Nicolas, Charbonnier and de Lemos 1 , Reference Manyam, Walters, Keller and Ghobrial 5 Although the likelihood of co-occurrence of Parkinson’s disease and IBGC cannot be excluded, brain calcification on CT scan along with SLC20A2 mutation in our case highlights the possibility of IBGC presenting as late-onset levodopa-responsive parkinsonism.

Statement of Authorship

NK undertook conception, design, and writing of the first manuscript. MJ undertook manuscript review and critique.

Disclosures

NK reports no disclosures relevant to the manuscript. MJ has received speaker and consultant honoraria from Merz Pharmaceuticals, Allergan, and AbbVie; research grants from CIHR, AMOSO, Allergan, Merz Pharmaceuticals, and Lawson Health Research Institute; is part of the AGEWELL Network of Centers of Excellence (NCE) of Canada program; and has served on advisory boards of Allergan, Boston Scientific, AbbVie. and Merz Pharmaceuticals.

References

1. Nicolas, G, Charbonnier, C, de Lemos, RR, et al. Brain calcification process and phenotypes according to age and sex: lessons from SLC20A2, PDGFB, and PDGFRB mutation carriers. Am J Med Genet Part B Neuropsychiatr Genet. 2015;168:586-594.Google Scholar
2. Savino, E, Soavi, C, Capatti, E, et al. Bilateral strio-pallido-dentate calcinosis (Fahr’s disease): report of seven cases and revision of literature. BMC Neurol. 2016;16:165.Google Scholar
3. Manyam, BV, Walters, AS, Narla, KR. Bilateral striopallidodentate calcinosis: clinical characteristics of patients seen in a registry. Mov Disord. 2001;16:258-264.Google Scholar
4. Lemos, RR, Ramos, EM, Legati, A, et al. Update and mutational analysis of SLC20A2: a major cause of primary familial brain calcification. Hum Mutat. 2015;36:489-495.CrossRefGoogle Scholar
5. Manyam, BV, Walters, AS, Keller, IA, Ghobrial, M. Parkinsonism associated with autosomal dominant bilateral striopallidodentate calcinosis. Park Relat Disord. 2001;7:289-295.CrossRefGoogle ScholarPubMed
Figure 0

Figure 1 Noncontrast CT of the brain showing bilateral calcifications in the basal ganglia and thalamus (A), subcortical white matter (B), and cerebellum (C).